Global Medical SEC Filings

Global Medical REIT Inc. is issuing a new series of preferred stock to raise capital through an underwritten public offering. The company agreed to sell 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at a public offering price of $25.00 per share, with a 30-day option for underwriters to purchase up to an additional 300,000 shares at the same price to cover over-allotments. The offering is expected to close on November 20, 2025, subject to customary conditions.

In connection with this, the operating partnership amended its agreement to allow issuance of up to 2,300,000 Series B Preferred Units with a $25.00 per unit liquidation preference, designed to mirror the economic terms of the preferred stock. The company intends to contribute the net proceeds from the Series B Preferred Stock to the operating partnership in exchange for an equal number of these units. Articles Supplementary designate 2,300,000 preferred shares as Series B, and if distributions on the Series B are not declared for any period, the company’s ability to pay distributions or make redemptions on junior or parity stock will be subject to specified restrictions.

Global Medical REIT Inc. (GMRE)$31.91 per share. Following this transaction, the officer beneficially owns 3,000 shares held directly. This filing reflects a personal investment decision by a senior financial executive rather than a corporate-level financing or strategic transaction.

Global Medical REIT Inc. (GMRE) reported insider share purchases by its CEO, President and Director on a Form 4. On 11/14/2025, the executive bought 4,093 shares of common stock at $32.41 per share and another 5,907 shares at $32.70 per share in open-market purchases. Following these transactions, the executive beneficially owns 44,774 shares directly and 3,404 shares indirectly through a spouse. The filing explains that the share amounts are presented on a post-split basis after a 1-for-5 reverse stock split completed on September 19, 2025, which also involved cash in lieu of a fractional share.

Global Medical REIT Inc. (GMRE) launched a primary offering of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at $25.00 per share. The underwriting discount is $0.7875 per share, for gross proceeds of $50,000,000 and proceeds before expenses of $48,425,000. The company estimates net proceeds of approximately $48.1 million, or approximately $55.4 million if the 300,000‑share over‑allotment option is exercised in full.

Dividends accrue at 8.00% of the $25.00 liquidation preference ($2.00 per share annually), payable quarterly, with the first, a pro rata $0.388 per share, scheduled for January 31, 2026 to holders of record on January 15, 2026. The shares are perpetual, callable at the company’s option on or after November 20, 2030 at $25.00 plus accrued and unpaid dividends, and feature a Change of Control conversion right and special optional redemption.

GMRE intends to apply to list the Series B on the NYSE as “GMRE PrB.” Net proceeds will be contributed to the Operating Partnership for general corporate purposes, including funding acquisitions and repaying indebtedness under the Credit Facility.

Global Medical REIT (GMRE): Schedule 13G/A Amendment No. 1 filed by Prudential Financial, Inc. reports beneficial ownership of 297,464 shares, representing 2.2% of the common stock as of the reported date. Prudential holds shared voting and dispositive power over all 297,464 shares and no sole power.

The filing classifies Prudential as an HC and includes subsidiaries with reported holdings: PGIM, Inc. 267,248 shares (2.0%), Prudential Insurance Company of America 28,620 (0.2%), and PGIM Quantitative Solutions LLC 1,596 (0.0%). The certification states the securities were acquired and are held in the ordinary course, not to change or influence control.

Global Medical REIT Inc. (GMRE) launched a primary offering of Series B Cumulative Redeemable Preferred Stock. The shares carry a $25.00 per share liquidation preference, pay cumulative cash dividends quarterly in arrears on January 31, April 30, July 31 and October 31, commencing on January 31, 2026 to holders of record as of January 15, 2026. The stock is perpetual, with optional redemption on or after 2030 at $25.00 plus accrued and unpaid dividends.

Upon a Change of Control, holders may convert into GMRE common stock (subject to a share cap and alternative consideration mechanics), unless the shares are called for redemption. Voting rights are limited to protective provisions and the right to elect two directors if six or more quarterly dividends are in arrears. GMRE’s charter includes a 9.8% ownership limit per class or series to support REIT qualification.

GMRE intends to apply to list the new preferred on the NYSE as “GMRE PrB”, with trading expected within 30 days after initial delivery. Net proceeds will be contributed to the operating partnership for general corporate purposes, including acquisitions and repaying indebtedness under the Credit Facility.

Global Medical REIT Inc. (GMRE) reported a third‑quarter 2025 net loss attributable to common stockholders of approximately $6.0 million, or $0.45 per diluted share, compared with net income of approximately $1.8 million, or $0.14 per diluted share, in the prior‑year period. For the nine months ended September 30, 2025, net loss attributable to common stockholders was approximately $4.7 million, or $0.35 per diluted share, versus a net loss of approximately $0.6 million, or $0.04 per diluted share, a year earlier.

Operating metrics were mixed. Same‑store cash NOI grew 2.7% year over year in Q3. Adjusted EBITDAre was $25.7 million for the quarter, with Net Debt/Annualized Adjusted EBITDAre at 6.9x. The portfolio was 95.2% occupied as of September 30, 2025, spanning approximately 5.2 million leasable square feet and generating $118.4 million annualized base rent. Weighted average lease term was 5.3 years. The rent mix was about 72% outpatient medical buildings, 25% inpatient rehabilitation facilities, hospitals, and LTACHs, and 3% other medical real estate.

Global Medical REIT Inc. (GMRE) filed its Q3 2025 report, showing steady rent growth but a quarterly loss driven by an impairment. Rental revenue was $37,036 in the quarter and total revenue was $37,229. Expenses rose on depreciation and interest, and the Company recorded a $6,281 impairment, resulting in net loss attributable to common stockholders of $6,001, or $0.45 per share.

For the nine months, total revenue reached $109,816 with operating cash flow of $51,977. GMRE acquired a five‑property medical real estate portfolio and completed five dispositions across Kansas, Oregon, Florida, Tennessee, and Illinois. The Company executed a 1‑for‑5 reverse stock split effective September 19, 2025, and reported 13,407,358 common shares outstanding as of November 3, 2025.

Balance sheet highlights include total assets of $1,273,238 and Credit Facility borrowings of $711,700 gross (Revolver $211,700, Term Loans $500,000). Subsequent to quarter end, on October 8, 2025 GMRE amended and restated its Credit Facility, extending the Revolver to October 2029, splitting Term Loan A into tranches maturing in 2029, 2030, and 2031, and removing the 0.10% SOFR spread adjustment.

Global Medical REIT Inc. (GMRE) furnished its Third Quarter 2025 results materials. On November 4, 2025, the company announced its financial position as of September 30, 2025 and operating results for the three and nine months ended September 30, 2025. The earnings release (Exhibit 99.1) and earnings supplemental (Exhibit 99.2) were posted to its website and furnished with this report.

The materials are furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference into other filings.